<?xml version="1.0" encoding="UTF-8"?>
<p>Valganciclovir is a pro-drug of GCV that inhibits replication of adenoviral genomic DNA via blockade of HAdV DNA polymerase. However, because HAdV lacks thymidine kinase, a known target for valganciclovir, it would likely become a challenge in the treatment of adenoviral keratoconjunctivitis.
 <xref rid="CIT0047" ref-type="bibr">47</xref>
</p>
